Chemo plus observation versus observation alone after colon cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding CAPEOX chemotherapy after surgery can help people with colon cancer who have a “positive MRD” blood test result (meaning tiny amounts of cancer may still be present). It compares chemo versus active observation to see if chemo improves outcomes while keeping safety in mind.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had colon or rectal cancer confirmed by pathology, and it is stage I or stage II.
- Your blood test for MRD (ctDNA) was positive 7–21 days after surgery using the MinerVa MRD test.
- You can do normal daily activities most of the time (ECOG 0–1).
- You did not receive chemotherapy before surgery, and you were eligible for active surveillance afterward (no adjuvant chemo) based on standard practice/guidelines.
- Your surgery samples are available for extra lab testing (molecular diagnostics).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
This trial is for people with early-stage colon cancer (stage II high-risk or stage III low-risk) that is not MSI-H. It uses a blood test (MRD) to see if you can safely delay or skip extra chemotherapy after surgery, based on whether the test finds any leftover cancer cells.
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
This Phase 3 study compares two schedules of a colon cancer chemo combination: starting before surgery or starting after surgery. It aims to see which timing helps people live longer and lowers cancer coming back.
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.